Limitations in Localising and Killing Tumours Using Radiolabelled Antibodies^[*]

Radiolabelled antibodies against tumours are being studied intensely for their use in tumour detection and tumour destruction. Although a host of different tumour types can be localised, results at present are no better than other scanning techniques. In addition no tumour has been eradicated using labelled antibodies. Dramatic improvements will depend upon a fuller understanding of tumour cell biology and optimising all the parameters involved.

Zusammenfassung

Radioaktiv markierte Antikörper gegen Tumore wurden bezüglich ihrer Anwendung zur Tumorortung und Zerstörung intensiv untersucht. Obwohl eine große Anzahl unterschiedlicher Tumore lokalisiert werden kann, sind die Resultate gegenwärtig nicht besser als die mit anderen Scan- Techniken. Außerdem konnte kein Tumor durch Anwendung markierter Antikörper ausgerottet werden. Eine dramatische Verbesserung wird von einem vollständigeren Verständnis der Tumorzellbiologie und einer Optimierung aller einbezogenen Parameter abhängen.

• REFERENCES

• 1 Goldenberg D. M, Deland F, Kim E. et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localisation of diverse cancers by external photoscanning. New Engl. J. Med 1978; 298: 1384-8.
• 2 Bradwell A. R, Fairweather D. S, Dykes P. W, Keeling A, Vaughan A, Taylor J. Limiting factors in the localisation of tumours with radiolabeled antibodies. Immunology Today 1985; 06: 163-70.
• 3 Berche C, Mach J. P, Lumbroso J. D. et al. Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: First clinical results using radiolabele d monoclonal antibodies against carcinoembryonic antigen. Brit. med. J 1982; 285: 1447-51.
• 4 Mach J-P, Forni M, Ritschard J. et al. Use of radiolabeled monoclonal anti CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunology Today 1981; 02: 239-49.
• 5 Farrands P. A, Perkins A. C, Pimm M. V. et al. Radioimmmunodetection of human colorectal cancers by an antitumour monoclonal antibody. Lancet 1982; 11: 397-400.
• 6 Burraggi G. L, Callegaro L, Mariani G. et al. Imaging with ¹³¹I labelled monoclonal antibodies to a high molecular weight melanoma-associated antigen in patients with melanoma: Efficacy of whole immunoglobulin and its F(ab)₂ fragments. Cancer Res 1985; 45: 3378-85.
• 7 Leichner P. K, Klein J. L, Siegelman K. et al. Dosimetry of ¹³¹I labelled anti ferritin in hepatoma: Specific activities in tumour and liver. Cancer Treat. Rep 1983; 67: 647-58.
• 8 Ellis F. The relationship of biological effect to dose-time fractionation factors in radiotherapy. Curr. Topics Radiat. Res 1968; 04: 359-97.
• 9 Ettinger D. S, Order S. E, Wharam M. D. et al. Phase I—II study of isotopi immunoglobulin therapy for primary liver cancer. Cancer Treat. Rep 1982; 66: 289-97.
• 10 Goodwin D, Meares C, Diamanti C. et al. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumour imaging proteins. Eur. J. nucl. Med 1984; 09: 209-15.